[FLXN] Flexion Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.71 Change: 2.14 (11.52%)
Ext. hours: Change: 0 (0%)

chart FLXN

Refresh chart

Strongest Trends Summary For FLXN

FLXN is in the medium-term up 42% above S&P in 3 months. In the long-term down -49% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.24% ROE-21.88% ROI
Current Ratio32.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-3.69 M Cash From Investing Activities-62.47 M Cash From Operating Activities-9.98 M Gross Profit
Net Profit-9.17 M Operating Profit-9.01 M Total Assets141.02 M Total Current Assets134.24 M
Total Current Liabilities4.16 M Total Debt Total Liabilities4.19 M Total Revenue
Technical Data
High 52 week19.6 Low 52 week9.07 Last close14.15 Last change2.39%
RSI43.06 Average true range0.79 Beta1.41 Volume629.96 K
Simple moving average 20 days1.12% Simple moving average 50 days9.85% Simple moving average 200 days14.99%
Performance Data
Performance Week4.12% Performance Month-2.82% Performance Quart28.64% Performance Half34%
Performance Year-23.01% Performance Year-to-date25% Volatility daily2.59% Volatility weekly5.79%
Volatility monthly11.87% Volatility yearly41.12% Relative Volume286.22% Average Volume623.19 K
New High New Low

News

2019-11-11 07:30:00 | Flexion Therapeutics Presents ZILRETTA® triamcinolone acetonide extended-release injectable suspension Efficacy Data at the AAHKS and ACR Annual Meetings

2019-11-08 18:07:04 | Edited Transcript of FLXN earnings conference call or presentation 7-Nov-19 9:30pm GMT

2019-11-07 19:15:12 | Flexion Therapeutics FLXN Reports Q3 Loss, Tops Revenue Estimates

2019-11-07 16:01:00 | Flexion Therapeutics Reports Third-Quarter 2019 Financial Results and Recent Business Highlights

2019-11-04 07:48:46 | Before You Buy Flexion Therapeutics, Inc. NASDAQ:FLXN, Consider Its Volatility

2019-11-01 16:40:06 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-10-31 16:30:05 | Flexion Therapeutics to Report Third-Quarter 2019 Financial Results on November 7, 2019

2019-10-31 14:20:56 | Is Flexion Therapeutics Inc FLXN A Good Stock To Buy?

2019-10-31 07:30:05 | Flexion Therapeutics Announces FDA Clearance of the Investigational New Drug Application for FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis

2019-10-24 15:57:22 | 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts

2019-10-14 07:00:00 | Flexion Therapeutics Announces Extended FDA Review of Supplemental New Drug Application for ZILRETTA®

2019-10-14 00:17:21 | 3 Top Biotech Stocks With Major Catalysts in October

2019-10-13 16:33:09 | The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings

2019-10-11 08:56:12 | Do Options Traders Know Something About Flexion Therapeutics FLXN Stock We Don't?

2019-10-04 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-10-04 08:40:06 | Health Check: How Prudently Does Flexion Therapeutics NASDAQ:FLXN Use Debt?

2019-10-02 09:00:00 | Former NY Yankees Outfielder Chris Dickerson Teams Up With Flexion Therapeutics to Raise Awareness of Impact of Osteoarthritis OA

2019-09-30 09:04:20 | Flexion Therapeutics to Present at the 2019 Cell & Gene Meeting on the Mesa

2019-09-23 09:00:00 | Flexion Therapeutics Sponsors a Memorial to the Victims of the Opioid Crisis to Raise Awareness of the Tragic Consequences of the Opioid Epidemic Across the U.S.

2019-09-18 09:31:01 | Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

2019-09-10 07:36:12 | The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris

2019-09-09 16:01:00 | Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

2019-09-06 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-09-04 09:55:01 | Flexion Therapeutics, Inc. FLXN Shares March Higher, Can It Continue?

2019-09-04 08:23:35 | Need To Know: Flexion Therapeutics, Inc. NASDAQ:FLXN Insiders Have Been Buying Shares

2019-09-03 14:21:23 | In expense-laden biotech industry, here are the Mass. startups most in need of cash

2019-08-28 16:30:00 | Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference

2019-08-10 12:01:00 | 3 Healthcare Stocks With Rising Expectations

2019-08-07 17:45:05 | Edited Transcript of FLXN earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-07 16:26:02 | Flexion Therapeutics, Inc. FLXN Q2 2019 Earnings Call Transcript

2019-08-06 18:35:10 | Flexion Therapeutics FLXN Reports Q2 Loss, Tops Revenue Estimates

2019-08-06 16:01:00 | Flexion Therapeutics Reports Second-Quarter 2019 Financial Results and Recent Business Highlights

2019-08-05 08:53:30 | How Should Investors Feel About Flexion Therapeutics, Inc.'s NASDAQ:FLXN CEO Pay?

2019-08-02 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-07-30 16:30:00 | Flexion Therapeutics to Report Second-Quarter 2019 Financial Results on August 6, 2019

2019-07-30 10:38:02 | Will Flexion Therapeutics FLXN Report Negative Q2 Earnings? What You Should Know

2019-07-15 07:30:00 | Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in Patients with Advanced Knee OA

2019-07-05 06:47:42 | Flexion Therapeutics, Inc. NASDAQ:FLXN: When Will It Breakeven?

2019-07-03 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-24 13:28:10 | Here’s What Hedge Funds Think About Flexion Therapeutics Inc FLXN

2019-06-20 09:00:00 | Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year

2019-06-18 16:30:00 | Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

2019-06-07 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-05 08:30:00 | Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis

2019-05-30 06:58:51 | If You Had Bought Flexion Therapeutics NASDAQ:FLXN Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today

2019-05-20 12:48:46 | These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month

2019-05-14 16:30:00 | Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

2019-05-12 21:50:08 | Here’s What Hedge Funds Think About Flexion Therapeutics Inc FLXN

2019-05-10 13:06:21 | Flexion Therapeutics, Inc. FLXN Q1 2019 Earnings Call Transcript

2019-05-10 07:30:00 | Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® triamcinolone acetonide extended-release injectable suspension